JPWO2019191598A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019191598A5 JPWO2019191598A5 JP2020551971A JP2020551971A JPWO2019191598A5 JP WO2019191598 A5 JPWO2019191598 A5 JP WO2019191598A5 JP 2020551971 A JP2020551971 A JP 2020551971A JP 2020551971 A JP2020551971 A JP 2020551971A JP WO2019191598 A5 JPWO2019191598 A5 JP WO2019191598A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- gram
- acid sequence
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 241000894006 Bacteria Species 0.000 claims 14
- 230000004048 modification Effects 0.000 claims 14
- 238000006011 modification reaction Methods 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 13
- 230000003115 biocidal Effects 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 206010060945 Bacterial infection Diseases 0.000 claims 7
- 241000894007 species Species 0.000 claims 7
- -1 cefepim Chemical compound 0.000 claims 6
- 239000003242 anti bacterial agent Substances 0.000 claims 5
- LKCWBDHBTVXHDL-RMDFUYIESA-N Amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 4
- MQTOSJVFKKJCRP-BICOPXKESA-N Azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 4
- 229960003644 Aztreonam Drugs 0.000 claims 4
- WZPBZJONDBGPKJ-VEHQQRBSSA-N Aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 4
- 108010078777 Colistin Proteins 0.000 claims 4
- YMDXZJFXQJVXBF-STHAYSLISA-N FOSFOMYCIN Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 claims 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 4
- 229960002182 IMIPENEM Drugs 0.000 claims 4
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N IMIPENEM Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 4
- 229960000707 Tobramycin Drugs 0.000 claims 4
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 4
- 229960004821 amikacin Drugs 0.000 claims 4
- 229960004099 azithromycin Drugs 0.000 claims 4
- 229960003346 colistin Drugs 0.000 claims 4
- XDJYMJULXQKGMM-RVYUQJQSSA-N colistin A Chemical compound CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O XDJYMJULXQKGMM-RVYUQJQSSA-N 0.000 claims 4
- 229960002518 gentamicin Drugs 0.000 claims 4
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 3
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 3
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 3
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 3
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 3
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 3
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 3
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 3
- 238000006640 acetylation reaction Methods 0.000 claims 3
- 238000007112 amidation reaction Methods 0.000 claims 3
- 229960003405 ciprofloxacin Drugs 0.000 claims 3
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 3
- 229940079866 intestinal antibiotics Drugs 0.000 claims 3
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 3
- 238000003259 recombinant expression Methods 0.000 claims 3
- GSDSWSVVBLHKDQ-JTQLQIEISA-N (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims 2
- ORFOPKXBNMVMKC-DWVKKRMSSA-O (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-O 0.000 claims 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N Cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims 2
- 229960004682 Cefoperazone Drugs 0.000 claims 2
- 229960000484 Ceftazidime Drugs 0.000 claims 2
- AVAACINZEOAHHE-VFZPANTDSA-N Doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims 2
- DMJNNHOOLUXYBV-PQTSNVLCSA-N Meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims 2
- JQXXHWHPUNPDRT-ZNQWNCHJSA-N O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)Nc2c(O)c3c(O)c4C)C)OC)c4c1c3c(O)c2C=NN1CCN(C)CC1 Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)Nc2c(O)c3c(O)c4C)C)OC)c4c1c3c(O)c2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-ZNQWNCHJSA-N 0.000 claims 2
- IVBHGBMCVLDMKU-GXNBUGAJSA-N Piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims 2
- 229940081190 Rifampin Drugs 0.000 claims 2
- 229960000895 doripenem Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960000308 fosfomycin Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229960003376 levofloxacin Drugs 0.000 claims 2
- 229960002260 meropenem Drugs 0.000 claims 2
- 229960002292 piperacillin Drugs 0.000 claims 2
- 229960001225 rifampicin Drugs 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- OHKOGUYZJXTSFX-IRHHVTTKSA-N (2S,5R,6R)-6-[(2-carboxy-2-thiophen-3-ylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C=1C=CSC=1 OHKOGUYZJXTSFX-IRHHVTTKSA-N 0.000 claims 1
- 241000588626 Acinetobacter baumannii Species 0.000 claims 1
- 229920002676 Complementary DNA Polymers 0.000 claims 1
- 241000588914 Enterobacter Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 1
- 229940045505 Klebsiella pneumoniae Drugs 0.000 claims 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims 1
- 108010093965 Polymyxin B Proteins 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 claims 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 206010039447 Salmonellosis Diseases 0.000 claims 1
- 241000607768 Shigella Species 0.000 claims 1
- 206010040550 Shigella infection Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000000295 complement Effects 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000002101 lytic Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229960005266 polymyxin B Drugs 0.000 claims 1
- 229920000024 polymyxin B Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650235P | 2018-03-29 | 2018-03-29 | |
| US62/650,235 | 2018-03-29 | ||
| PCT/US2019/024854 WO2019191598A1 (en) | 2018-03-29 | 2019-03-29 | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519311A JP2021519311A (ja) | 2021-08-10 |
| JPWO2019191598A5 true JPWO2019191598A5 (ru) | 2022-04-01 |
Family
ID=68058481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551971A Pending JP2021519311A (ja) | 2018-03-29 | 2019-03-29 | 抗微生物性バクテリオファージ由来ポリペプチド及びグラム陰性細菌に対するそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210330738A1 (ru) |
| EP (1) | EP3773669A4 (ru) |
| JP (1) | JP2021519311A (ru) |
| KR (1) | KR20210005027A (ru) |
| CN (1) | CN112368010A (ru) |
| AU (1) | AU2019245333A1 (ru) |
| BR (1) | BR112020019010A2 (ru) |
| CA (1) | CA3096236A1 (ru) |
| IL (1) | IL277399A (ru) |
| MX (1) | MX2020010071A (ru) |
| WO (1) | WO2019191598A1 (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200136980A (ko) | 2018-03-29 | 2020-12-08 | 콘트라펙트 코포레이션 | 리신-항미생물 펩타이드(amp) 폴리펩타이드 작제물, 리신, 이를 인코딩하는 단리된 폴리뉴클레오타이드 및 이의 용도 |
| US20220401514A1 (en) * | 2019-07-05 | 2022-12-22 | Contrafect Corporation | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria |
| JP2023502940A (ja) * | 2019-11-14 | 2023-01-26 | コントラフェクト コーポレイション | 溶解素－抗微生物ペプチド（ａｍｐ）ポリペプチドコンストラクト、溶解素、それをコードする単離ポリヌクレオチド及びその使用 |
| WO2021211303A1 (en) * | 2020-04-14 | 2021-10-21 | Contrafect Corporation | Antiviral, bacteriophage-derived polypeptides and their use against viruses |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2447823A1 (en) * | 2001-05-23 | 2002-11-28 | The University Of British Columbia | Diagnosis of vascular disease susceptibility using bacteriophage phi-cpn1 host chlamydia |
| US8022271B2 (en) * | 2003-05-16 | 2011-09-20 | North Carolina State University | Polyubiquitin Rubi3 promoter and 5' regulatory sequences |
| KR102274003B1 (ko) * | 2007-01-19 | 2021-07-08 | 카이 파마슈티컬즈 | 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형 |
| WO2010141135A2 (en) * | 2009-03-05 | 2010-12-09 | Trustees Of Boston University | Bacteriophages expressing antimicrobial peptides and uses thereof |
| WO2013138850A1 (en) * | 2012-03-19 | 2013-09-26 | Madeleine Pharmaceuticals Ρτy Ltd | Method of producing a recombinant peptide |
| JP7029805B2 (ja) * | 2015-09-17 | 2022-03-04 | コントラフェクト コーポレイション | グラム陰性菌に対して活性を有する溶解素ポリペプチド |
| KR20200136980A (ko) * | 2018-03-29 | 2020-12-08 | 콘트라펙트 코포레이션 | 리신-항미생물 펩타이드(amp) 폴리펩타이드 작제물, 리신, 이를 인코딩하는 단리된 폴리뉴클레오타이드 및 이의 용도 |
| US20210363511A1 (en) * | 2018-08-23 | 2021-11-25 | Contrafect Corporation | Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof |
| US20220401514A1 (en) * | 2019-07-05 | 2022-12-22 | Contrafect Corporation | Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria |
| JP2023502940A (ja) * | 2019-11-14 | 2023-01-26 | コントラフェクト コーポレイション | 溶解素－抗微生物ペプチド（ａｍｐ）ポリペプチドコンストラクト、溶解素、それをコードする単離ポリヌクレオチド及びその使用 |
| US20210324359A1 (en) * | 2020-04-17 | 2021-10-21 | Contrafect Corporation | Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in treating endocarditis |
-
2019
- 2019-03-29 KR KR1020207030981A patent/KR20210005027A/ko active Search and Examination
- 2019-03-29 JP JP2020551971A patent/JP2021519311A/ja active Pending
- 2019-03-29 EP EP19774811.4A patent/EP3773669A4/en active Pending
- 2019-03-29 CN CN201980036013.5A patent/CN112368010A/zh active Pending
- 2019-03-29 US US17/041,638 patent/US20210330738A1/en active Pending
- 2019-03-29 BR BR112020019010-1A patent/BR112020019010A2/pt unknown
- 2019-03-29 CA CA3096236A patent/CA3096236A1/en active Pending
- 2019-03-29 WO PCT/US2019/024854 patent/WO2019191598A1/en active Application Filing
- 2019-03-29 MX MX2020010071A patent/MX2020010071A/es unknown
- 2019-03-29 AU AU2019245333A patent/AU2019245333A1/en active Pending
-
2020
- 2020-09-16 IL IL277399A patent/IL277399A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018201931B2 (en) | Antimicrobial Agents | |
| AU758698B2 (en) | Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor | |
| JP2021506769A5 (ru) | ||
| KR20180052754A (ko) | 폐계면 활성제 존재하에서 저해된 항생제의 항균 작용을 회복/증진시키기 위한 라이신의 용도 | |
| US11180744B2 (en) | Acinetobacter lysins | |
| AU2016231141B2 (en) | Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection | |
| MX2013007313A (es) | Agentes antimicrobianos. | |
| JP2013502231A (ja) | エンドリシンＯＢＰｇｐＬＹＳ | |
| CN112166190A (zh) | 新抗微生物蛋白 | |
| RU2020128276A (ru) | МОДИФИЦИРОВАННЫЕ ЛИЗИНЫ PlySs2 И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ | |
| JPWO2019191633A5 (ru) | ||
| CN115397994B (zh) | 新型多肽、融合多肽和包含其的抗革兰氏阴性菌的抗生素 | |
| JPWO2019191598A5 (ru) | ||
| US20060258596A1 (en) | Antimicrobial agents | |
| RU2020131450A (ru) | Происходящие из бактериофагов противомикробные полипептиды и их применение против грамотрицательных бактерий | |
| RU2020129467A (ru) | Полипептидные конструкции лизин-противомикробный пептид (amp), лизины, выделенные полинуклеотиды, кодирующие их, а также варианты их применения | |
| JPWO2021180892A5 (ru) | ||
| KR101595976B1 (ko) | 황색포도알균에 특이적 항균 활성을 가지는 리신 융합 단백질 및 이의 용도 | |
| CN115927255B (zh) | 多肽和抗含有该多肽的革兰氏阴性菌的抗生素 | |
| JPWO2020206327A5 (ru) | ||
| JPWO2021097192A5 (ru) | ||
| RU2020118691A (ru) | Идентификация лизинов и их производных, обладающих антибактериальной активностью против pseudomonas aeruginosa | |
| WO2021069766A1 (es) | Proteínas víricas con actividad antibacteriana frente a escherichia coli |